HDAC9 and acute promyelocytic leukemia: In this study, we demonstrated that HMT inhibitor 3-Deazaneplanocin A and HDAC inhibitor Belinostat enhanced conventional treatment (Retinoic acid + Idarubicin) for acute promyelocytic leukemia in vitro and ex vivo.